Metabolic drugs in anti-ischemic therapy
| dc.contributor.author | Zakharenkova, A. | |
| dc.contributor.author | Візір, Марина Олександрівна | |
| dc.contributor.author | Vizir, Maryna | |
| dc.contributor.author | Визир, Марина Александровна | |
| dc.date.accessioned | 2017-12-13T09:30:56Z | |
| dc.date.available | 2017-12-13T09:30:56Z | |
| dc.date.issued | 2017-11 | |
| dc.description.abstract | The first drugs for anti-ischemic therapy were vitamins of group B, but their effectiveness was refuted in clinical trials. The next drug was trimetazidine, since it has a high cytoprotective effect. This drug is especially effective in patients with stable angina. But thiotriazoline is a new anti-ischemic drug that includes anti-ischemic, metabolic and antioxidant activity with minimal side effects. Summing up, given the good tolerability, efficacy and safety, thiotriazoline can be recommended as a remedy of metabolic therapy for the treatment of IHD in the elderly. | ru_RU |
| dc.identifier.citation | Zakharenkova A. Metabolic drugs in anti-ischemic therapy / A. Zakharenkova // Science and Life : Proceedings of articles the international scientific conference, Skleněný Můstek, Karlovy Vary, Czech Republic, 16–17 November 2017. – Karlovy Vary, 2017. – P. 59–64. | ru_RU |
| dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/18814 | |
| dc.language.iso | en | ru_RU |
| dc.publisher | Skleněný Můstek, Karlovy Vary, Czech Republic | ru_RU |
| dc.subject | anti-ischemic therapy | ru_RU |
| dc.subject | coronary heart disease | ru_RU |
| dc.subject | Trimetazidine | ru_RU |
| dc.subject | thiotriazoline | ru_RU |
| dc.title | Metabolic drugs in anti-ischemic therapy | ru_RU |
| dc.type | Article | ru_RU |